Clinical trials: Liraglutide
Diabetes Mellitus
A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in…
- Trial name
- NCT02059564
- Testing
- HM11260C, Victoza
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Type 1 Diabetes
Obesity Treatment to Improve Diabetes
As the obesity pandemic continues unabated, one can expect to see an increase in the prevalence of TID/T2D and associated CKD. As a result, death will rise, preceded by an increase in kidney failure, requiring dialysis and renal…
- Trial name
- OTID (NCT05390307)
- Testing
- Liraglutide / Semaglutide, Dapagliflozin, Liraglutide or Semaglutide / Dapagliflozin
- Where
- Kuwait
- Volunteers
- 60 people
- Sponsor
- Dasman Diabetes Institute
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus.
- Trial name
- PIONEER 4 (NCT02863419)
- Testing
- semaglutide, liraglutide
- Where
- 108 sites in United States, Croatia and 11 more
- Volunteers
- 711 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study of Tirzepatide in Overweight and Very Overweight Participants
The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight.
- Trial name
- NCT04311411
- Testing
- Tirzepatide, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 114 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Asia, Europe and North and South America. The aim of the trial is to investigate the effect of liraglutide versus placebo when added to basal insulin analogues with or without metformin in subjects with…
- Trial name
- NCT01617434
- Testing
- liraglutide
- Where
- 86 sites in United States, Argentina and 7 more
- Volunteers
- 451 people
- Sponsor
- Novo Nordisk A/S
Obesity
Anti-obesity Pharmacotherapy and Inflammation
This study evaluates the relationship between weight loss, circulating inflammatory markers and lipids from 24 patients before and after 6 months of pharmacotherapy as a standard of care for anti-obesity treatment
- Trial name
- NCT05756764
- Testing
- Semaglutide, Phentermine-Topiramate combination, Phentermine
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Obesity
Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery
This is a randomized, double-blinded, placebo-controlled trial of liraglutide versus placebo over a follow-up period of 12 months in patients at least 18 months following Roux-en-Y gastric bypass (RYGB) who are experiencing…
- Trial name
- NCT03048578
- Testing
- Saxenda
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- NYU Langone Health
Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
A diagnosis of gestational diabetes mellitus (GDM)has significant implications for the future health of the mother. GDM is often the culmination of years of unrecognized and unmodified diabetes risk factors that lead to overt and…
- Conditions
- Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance
- Trial name
- NCT01234649
- Testing
- Metformin XR plus liraglutide
- Where
- United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Woman's
Metabolism and Nutrition Disorder, Obesity
A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.
This trial is conducted in Europe. The aim of this trial is to investigate the effects of liraglutide on gallbladder emptying in overweight and obese subjects.
- Trial name
- NCT02717858
- Testing
- liraglutide
- Where
- Denmark
- Volunteers
- 52 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
The Lira Pump Trial
A randomized placebo-controlled clinical trial investigating the effects of Liraglutide as an add-on to intensive insulin therapy in overweight insulin pump treated type 1 diabetes patients in suboptimal glycemic control.
- Trial name
- NCT02351232
- Testing
- Liraglutide
- Where
- 2 sites in Denmark
- Volunteers
- 44 people
- Sponsor
- Hvidovre University Hospital
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) versus GLP-1 receptor agonist (GLP-1 RA) in hemoglobin A1c (HbA1c) change.
- Trial name
- LixiLan-G (NCT02787551)
- Testing
- Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide
- Where
- 124 sites in United States, Canada and 7 more
- Volunteers
- 514 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of insulin degludec/liraglutide in insulin naïve subjects inadequately controlled…
- Trial name
- DUAL™IV (NCT01618162)
- Testing
- insulin degludec/liraglutide
- Where
- 87 sites in United States, Bulgaria and 6 more
- Volunteers
- 435 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.
To investigate the effect of liraglutide on vascular injury induced hypoglycemia in patients with type 1 diabetes mellitus. The vascular damage is evaluated at investigating the changes of endothelial function
- Trial name
- DIAB-01 (NCT02109315)
- Testing
- Vitamine C, Liraglutide 6 mg
- Where
- Spain
- Sponsor
- Anna Cruceta
Type 2 Diabetes
Human Bioequivalence Test of Liraglutide Injection
To evaluate the bioequivalence of The liraglutide injection produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Victoza® produced by Novo Nordisk (China) Pharmaceutical Co., Ltd for single dose in healthy subjects,so…
- Trial name
- NCT05029076
- Testing
- Liraglutide injection, Victoza
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Diabetes Mellitus, Type 2
Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
The aim of this study is to assess the safety and effectiveness of Xultophy® initiated according to label in adults with type 2 diabetes mellitus (T2DM) under routine clinical practice conditions.
- Trial name
- NCT04952779
- Testing
- Xultophy® (insulin degludec/liraglutide)
- Where
- 32 sites in South Korea
- Volunteers
- 750 people
- Sponsor
- Novo Nordisk A/S
Fatty Liver, Nonalcoholic, Diabetes Mellitus, Type 2
Anti-diabetic Drugs and Fatty Liver Management
Type 2 DM is one of the major risk factors for development of non-alcoholic fatty liver disease. The pooled prevalence of fatty liver among diabetics is 54% (95% CI 45%-64%).
- Trial name
- NCT05041673
- Testing
- Metformin
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Alexandria University
Diabetes, Diabetes Mellitus, Type 2
To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c
This trial is conducted in North America (the United States of America (USA) and Mexico). The trial is designed to evaluate the effects of treatment with liraglutide versus glimepiride in subjects with type 2 diabetes.
- Trial name
- LEAD-3 (NCT00294723)
- Testing
- liraglutide, glimepiride
- Where
- 117 sites in United States, Mexico and 1 more
- Volunteers
- 746 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
This is a randomised, open-label, multicenter, active-controlled, parallel-design, phase III clinical trial. The purpose of this study to compare the efficacy and safety of Insulin Degludec/Liraglutide Injection with XULTOPHY®…
- Trial name
- NCT06559722
- Testing
- Insulin Degludec/liraglutide Injection, XULTOPHY®
- Volunteers
- 510 people
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
Atrial Fibrillation, Recurrence
Outcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF )
Atrial Fibrillation (AF) is the most common abnormal heart rhythm(arrhythmia) affecting about one in 40 people in England. Patients with AF often have symptoms ranging from palpitations and breathlessness, and a small number of…
- Conditions
- Atrial Fibrillation, Recurrence, Overweight and Obesity, Liraglutide
- Trial name
- GOAL-AF (NCT05221229)
- Testing
- Liraglutide plus upstream risk factors modification advice and consultation
- Where
- United Kingdom
- Volunteers
- 29 people
- Sponsor
- University Hospital Birmingham
Diabetes, Diabetes Mellitus, Type 2
Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Asia. The aim of this study is to investigate the safety profile of liraglutide (Victoza®) under normal conditions of use in Korean subjects with type 2 diabetes mellitus.
- Trial name
- NCT01821846
- Testing
- liraglutide
- Where
- 7 sites in South Korea
- Volunteers
- 64 people
- Sponsor
- Novo Nordisk A/S